Spinal biologics encompass materials that can be utilized in case of bone fusion surgery, spinal cord injury, and degenerative disk disease. Ten years ago, the spine treatment market constituted 75% traditional rods and plates made of metals and 25% biologics. However, since metals are inert materials, they did not stimulate the bone regeneration process. On the other hand, biological materials are proteins that can attract and stimulate cells, promote fusion, and help in the bone healing process. . The global spine biologics market is expected to reach $2.4 Billion by 2020, at a CAGR of 4.4% during the forecast period from 2015 to 2020.

The global market was valued at $1.90 Billion in 2014 and is expected to reach $2.4 Billion by 2020, at a CAGR of 4.4% from 2015-2020.

By product type, the spine biologics market is categorized into four types, namely, bone graft substitutes, bone grafts, platelet-rich plasma (PRP), and bone marrow aspirate concentrate therapy. In 2014, the bone graft substitutes segment contributed the largest share of 84.1% to the global market.

By surgery type, the market is segmented into: anterior cervical discectomy and fusion (ACDF), transforaminal lumbar interbody fusion (TLIF), anterior lumbar interbody fusion (ALIF), lateral lumbar interbody fusion (LLIF), and other surgeries. The ACDF segment contributed the largest share to the global spine biologics market in 2014, followed by the transforaminal lumbar interbody fusion (TLIF) segment.

The global spine biologics market has been categorized by regions into North America, Europe, Asia-Pacific, and the Rest of the World. North America is the most dominant region in the global market, followed by Europe. Bone graft substitute segment dominated the North American spine biologics market.

Some of the major players in the spine biologics market are Medtronic Inc. (U.S.), DePuy Synthes Companies (U.S.), Zimmer Holding Inc. (U.S.), Nuvasive Inc. (U.S.), Stryker Corporation (U.S.), Orthofix international N.V. (U.S.), K2M Inc. (U.S.), Exactech Inc. (U.S.), Wright Medical Technology Inc. (U.S.), and others.

Key stakeholders of this market include spine biologics manufacturing companies, medical device distributors, healthcare institutions (hospitals, medical schools and governing bodies), health insurance players, research and consulting firms, and regulatory authorities (FDA).

Scope of the Report : Spine Biologics Market

This report categorizes the global market for spine biologics on the basis of Product type, Surgery type, and region.

Market Segmentation, by Product Type:

Based on type, the global spine biologics market is segmented into Bone Graft Substitutes, Bone Grafts, Platelet Rich Plasma (PRP), and Bone Marrow Aspirate Concentrate (BMAC) Therapy.

Market Segmentation, by Surgery type:

Based on surgery type, the global spine biologics market is classified into Anterior Cervical Discectomy and Fusion (ACDF), Transforamenal Lumbar Interbody Fusion (TLIF), Anterior Lumbar Interbody Fusion (ALIF), Lateral Lumbar Interbody Fusion (LLIF), and Other Surgeries.

Market Segmentation, by Region:

The regional analysis covers North America, Europe, Asia-Pacific, and RoW.

Customization Options : Spine Biologics Market

Along with market data, customize the MarketsandMarkets study to meet your company�s specific needs. Customize to get a comprehensive summary of the industry standards and a detailed analysis of the following parameters:

Product Analysis

Usage pattern (in-depth trend analysis) of products (segment-wise)

Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country- and sub segment-level

Spine Surgeons/ Doctors Perception Analysis



Fast turn-around analysis of spine surgeons and doctors responses to market events and trends

Spine surgeons and Physicians opinions about products from different companies

Region-specific spine surgeons qualitative inputs on spine biologics

Regulatory Framework

Listing the regulatory issues of major countries if they are adversely affecting the business/market/industry

Studying the reimbursements and its related impact offered by the government

Competitive Intelligence

Market share of region-specific players in the market

Crucial developments and strategies of the key companies inculcated in their portfolio

The report on global spinal biologics market analyzes and segments the market on the basis of product, surgery type, and region. It analyzes the competitive developments, such as alliances, joint ventures, and mergers & acquisitions in the global spine biologics market. This market is also analyzed with an explicit focus on the high-growth applications and fastest-growing market segments.

The spine biologics devices are used in spine surgery as lieu allografts as well as a support for bones in and around the spinal region. These devices offer numerous benefits over materials such as pedicle rods and screws that are used in spine fusion. Since metals are inert in nature, they do not stimulate or activate cellular growth or alter cellular functions such as natural healing. Spine biologics, on the other hand, activate cellular growth by stimulating spine fusion. The driving forces for global spinal biologics market include rising incidence of spinal disorders, rising healthcare expenditure in developing nations owing to growing income levels, rising obesity cases, awareness on the newly developed spine treatment techniques and devices, technological advancements, and rising demand of minimally invasive spine surgeries. The major restraints for this market include lack of expertise, lack of patient awareness, cost of surgery, and unfavourable reimbursement scenario.

Traditionally, allografts were considered as a gold standard for replenishment of the spinal bones. However, drawbacks such as donor site complications, high surgical cost, lengthy surgical surgeries, and longer recovery time resulted in a shift from allograft bones to other biological alternatives, such as bone morphogenetic proteins (BMP), demineralized bone matrix (DBM), and bone substitutes. BMPs stimulate the process of bone growth and spinal fusion. They offer advantages such as minimal postoperative pain, shorter hospital stays, faster recovery, in addition to eliminating the need of harvesting bone from patient. Currently, clinical investigation in order to increase its application in spine degenerative disc surgery is in process.

The global market was dominated by North America in 2014, followed by Europe, Asia-Pacific, and Rest of the World (RoW). North America is expected to continue to lead the spine biologics market in coming years, followed by Europe. The market in Asia-Pacific is projected to grow at the highest CAGR of 7.6% during the forecast period from 2015 to 2020. The growth in this region is expected to be driven by rising aging population, increasing per capita healthcare expenditure, and rising demand from China and India due to their respective large population base.

The global spine biologics market was valued at $1.9 billion in 2014. The North American market contributed the largest share to the global market in 2014 with the U.S. dominating the North America market.